Aligos Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-12$13.30 RISE2026-02-05$6.49 PEAK2026-04-14$8.74 123d | -51.2% 55d | Missed | Missed | — | — | +34.7% 68d | Missed |
DROP2025-09-05$11.34 RISE2025-11-13$6.07 PEAK2025-12-12$13.30 98d | -46.5% 69d | Missed | Missed | — | — | +119.0% 29d | Missed |
DROP2025-03-24$11.63 RISE2025-07-31$7.28 PEAK2025-09-05$11.34 165d | -37.4% 129d | Missed | Missed | — | — | +55.8% 36d | Missed |
DROP2025-01-06$45.62 RISE2025-04-10$3.99 PEAK2025-07-09$8.66 184d | -91.3% 94d | Missed | Missed | — | — | +117.0% 90d | Missed |
DROP2024-09-09$19.43 RISE2024-10-10$6.89 PEAK2025-01-06$45.62 119d | -64.5% 31d | Missed | Missed | — | — | +562.1% 88d | Missed |
DROP2024-04-08$26.75 RISE2024-08-06$11.18 PEAK2024-09-09$19.43 154d | -58.2% 120d | Missed | Missed | — | — | +73.9% 34d | Missed |
DROP2024-03-01$28.25 RISE2024-06-28$8.75 PEAK2024-09-09$19.43 192d | -69.0% 119d | Missed | Missed | — | — | +122.1% 73d | Missed |
DROP2023-10-04$19.90 RISE2024-02-13$15.95 PEAK2024-03-01$28.25 149d | -19.8% 132d | Missed | Missed | — | — | +77.1% 17d | Missed |
DROP2023-08-09$24.35 RISE2023-12-11$14.00 PEAK2024-03-01$28.25 205d | -42.5% 124d | Missed | Missed | — | — | +101.8% 81d | Missed |
DROP2023-01-18$52.75 RISE2023-03-31$21.85 PEAK2023-05-04$34.00 106d | -58.6% 72d | Missed | Missed | — | — | +55.6% 34d | Missed |
DROP2022-08-15$39.00 RISE2022-12-16$22.33 PEAK2023-01-18$52.75 156d | -42.8% 123d | Missed | Missed | — | — | +136.3% 33d | Missed |
DROP2022-07-20$40.00 RISE2022-11-09$22.35 PEAK2023-01-18$52.75 182d | -44.1% 112d | Missed | Missed | — | — | +136.0% 70d | Missed |
DROP2022-01-03$305.00 RISE2022-05-06$26.00 PEAK2022-06-07$40.00 155d | -91.5% 123d | Missed | Missed | — | — | +53.8% 32d | Missed |
DROP2021-11-08$442.25 RISE2022-02-23$55.25 PEAK2022-03-22$72.50 134d | -87.5% 107d | Missed | Missed | — | — | +31.2% 27d | Missed |
DROP2021-06-11$840.00 RISE2021-10-11$338.75 PEAK2021-11-08$442.25 150d | -59.7% 122d | Missed | Missed | — | — | +30.6% 28d | Missed |
1–15 / 18 1 / 2 | |||||||
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.
SOUTH SAN FRANCISCO, Calif., May 13, 2026 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver...
Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results and raising FY26 sales guidance.
Aligos Therapeutics (ALGS) beat Q1 2026 estimates with $2.83M revenue and a narrower loss, sparking a 6% after-hours stock surge amid a major licensing deal.
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2026. “I am pleased to continue building on our progress made so far in 2026,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Offic
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the analyst consensus estimate of $(2.28) by 3.07 percent. This is a 4.74 percent decrease over losses of $(2.11) per share from
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical com
SOUTH SAN FRANCISCO, Calif. - Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on improving patient outcomes through best - in - class therapies for liver and viral...
Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.
Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.
Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.
Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING®, to treat chronic HBV infection SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmace
MYSE: 280% | Myseum shares are trading higher. The company announced a rebrand to Myseum.AI. ALGS: 48% | Aligos Therapeutics shares are trading higher after the company announced that it has entered into
Under the terms of the agreement, Aligos will receive an upfront milestone of $25M USD and is eligible to receive up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit
Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not metStudy drugs were well-tolerated by participantsTopline data expected in 2027, guidance remains unchanged SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALGS | -6.40% | -18.16% | -38.84% | +7.75% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.37% | -12.45% | -35.40% | -4.94% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -1.25 | — | — |
| 2026-05-07 | -2.37 | -2.21 | +6.77% |
| 2026-03-05 | -2.49 | -1.91 | +23.21% |
| 2025-11-06 | -2.01 | -3.04 | -51.24% |
| 2025-08-06 | -2.53 | -1.53 | +39.64% |
| 2025-05-06 | -3.15 | 5.12 | +262.37% |
| 2025-03-10 | -3.67 | -13.10 | -256.95% |
| 2024-11-06 | -1.32 | -3.07 | -131.70% |
| 2024-08-06 | -4.00 | 0.75 | +118.75% |
| 2024-05-07 | -4.75 | -5.50 | -15.79% |
| 2024-03-12 | -6.75 | -5.50 | +18.52% |
| 2023-11-02 | -11.87 | -10.25 | +13.68% |
| 2023-08-03 | -12.37 | -10.75 | +13.13% |
| 2023-05-04 | -12.12 | -13.25 | -9.28% |
| 2023-03-09 | -12.67 | -12.75 | -0.66% |
| 2022-11-02 | -14.52 | -11.00 | +24.25% |